BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40

Kazia Therapeutics Reports New Preclinical And Translational Data Showing Lead Asset Paxalisib Reduced Tumor Burden By 52% In MSS/pMMR Colorectal Cancer

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well Tolerated as Monotherapy and

Kazia Therapeutics Announces New Preclinical Data Showing Safety, Anti-Tumor Activity Of Paxalisib In HR+/HER2- Breast Cancer; First Patient Expected By Year-End 2026 And Full Enrollment By End Of 2027

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib

Kazia Therapeutics Announces Pricing Of $40M Underwritten Offering Of ADSs And Pre-Funded Warrants